Literature DB >> 8686481

Treatment of manic episodes: zuclopenthixol and clonazepam versus lithium and clonazepam.

G Gouliaev1, R W Licht, P Vestergaard, L Merinder, H Lund, L Bjerre.   

Abstract

For the treatment of acute mania, no single drug is sufficiently effective in daily clinical routine for all patients. Drug combinations are often prescribed but poorly investigated. The present study examined whether a treatment with a neuroleptic drug (zuclopenthixol) combined with a benzodiazepine (clonazepam) was superior to a treatment with lithium and the same benzodiazepine (lithium citrate and clonazepam). Twenty-eight hospitalized patients with a DSM-III-R manic episode were included, randomized to fixed drug doses and observed up to 28 days. Degree of mania, side effects and patients satisfaction with the treatment were registered. Approximately two thirds of the patients improved fully or partially on both drug combinations. Furthermore no statistically significant differences were found regarding acceptance and tolerance of the two drug combinations. The present drug combination are only two among several which deserve a thorough examination in order to prevent a random polypharmacy for treatment of mania.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686481     DOI: 10.1111/j.1600-0447.1996.tb09812.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  3 in total

1.  Lithium for acute mania.

Authors:  Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-06-01

Review 2.  The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.

Authors:  Per Bech
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

3.  Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.

Authors:  Taro Kishi; Toshikazu Ikuta; Yuki Matsuda; Kenji Sakuma; Makoto Okuya; Ikuo Nomura; Masakazu Hatano; Nakao Iwata
Journal:  Mol Psychiatry       Date:  2021-10-12       Impact factor: 13.437

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.